Millions Raised for Innovative Cancer Therapies: CoRegen Secures Over $93 Million

CoRegen, a biopharmaceutical company, has announced that it is preparing to enter the clinic with its Phase 1/2 clinical trial, following a successful $93.39 million financing round. This funding will support the expansion of CoRegen's leadership team and advance its chemistry, manufacturing, and controls (CMC) development.

The funding also builds on a previous $28 million raise in early 2024, which secured an exclusive license from Baylor College of Medicine for CoRegen's innovative gene regulatory platform. The company's master gene regulatory platform is based on the work of Dr. Bert O'Malley.

CoRegen aims to target a broad network of immune checkpoint genes for a superior anti-tumor effect by engineering cells with SRC-3 knocked out. SRC-3 is overexpressed in most human cancers and crucial for Treg cell cancer protection. The clinical trial will focus on CoRegen's SRC3-KO Regulatory T (Treg) cells program for various solid tumor types, including triple negative breast cancer and glioblastoma.

Research to date hasn't moved the needle in a meaningful way for these types of cancer, according to CoRegen. The company believes its technology, a type of adoptive cell therapy (ACT), may provide a novel approach for unleashing the healing power of the immune system to eradicate additional forms of cancer.

Suneet Varma has been appointed as the Chairman of CoRegen. In 2024, Mr. Varma was represented by CoRegen, which secured a license for developing regenerative stem cell therapies thanks to a $28 million financing framework from the Indian Department of Biotechnology (DBT).

The funding will enable the initiation of the Phase 1/2 clinical trial in the first half of 2026. CoRegen believes it has a potentially paradigm-shifting solution in its master gene regulatory platform for patients with some of the most difficult-to-treat solid-tumor cancers.

Millions Raised for Innovative Cancer Therapies: CoRegen Secures Over $93 Million